In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss emerging concerns about H5N1 avian influenza. 

Specific topics of discussion include:

• Patterns of transmission and what they indicate about the potential of person-to-person transmission. 
• Tools, tests, and processes that emerged in recent years that are making it easier to understand and track this virus. 
• Remaining unknowns about the virus and how it could evolve. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the progress of artificial intelligence (AI) and what’s next in this space.

Specific topics of discussion include:

• What’s driving the rapid acceleration of AI advancements.
• Ethical concerns and opportunities.
• How expenses, payment models, and culture influence AI advancements.
• The need to rethink training and education amid the rise of AI solutions.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich, Ph.D., a professor of laboratory medicine and pathology at Mayo Clinic and co-director of the Clinical Immunoassay Laboratory. They discuss Mayo Clinic’s plasma test for detecting Alzheimer’s disease and how it supports increased access and early detection. 

Specific topics of discussion include:

• The phospho-Tau 217 plasma test (Mayo ID: PT217) used to evaluate individuals aged 50 years and older with symptoms of cognitive impairment who are being assessed for Alzheimer’s disease and other causes of cognitive decline.
• The benefits of a blood test versus the other diagnostic methods for Alzheimer’s disease.
• Why early diagnosis is so important for quality of life and treatment planning.
• How tests like Mayo Clinic Laboratories’ PT217 may change the landscape of Alzheimer's research and treatment.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss locally acquired cases of malaria that have recently occurred in Texas and Florida.

Their discussion includes:

•  Why malaria may be reappearing after being eliminated in the United States in the 1950s.
• The importance of laboratory diagnostics in identifying and diagnosing different types of malaria.
• Testing options available through Mayo Clinic Laboratories for malaria and other mosquito-borne diseases. 

Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.

(00:32)
 Could you provide our listeners with a little bit about yourself and your background, please?

 

(01:35)
 Could you give us a brief overview of the newly developed urologic assays?

 

(03:51)
 Can you talk a little bit more about what patients should have this testing?

 

(07:24)
 Can you talk in more detail about the MayoComplete bladder and prostate panel?

 

(11:33)
 How are these results used in patient care?

 

(16:10)
 Is there anything else you would like to add?

The Centers for Disease Control and Prevention (CDC) issued a recent health advisory to remind healthcare providers to be on the lookout for cases of measles and to educate patients on measles prevention. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, to discuss why measles prevention continues to be critically important.

Specific topics of discussion include:

• A brief history of measles activity in the United States, and why measles cases are rising.
• Why the virus is so contagious, and how herd immunity applies to measles.
• Vaccination and prevention methods.
• Testing options available through Mayo Clinic Laboratories including:
  • Molecular testing to detect the viral RNA in urine (MEASU) and throat swabs (MEASR), 
  • Serology testing on serum to detect IgM (ROM) or IgG-class antibodies (ROPG), or serology testing on cerebrospinal fluid (ROC).

John Lieske, M.D., explains why it's now easier for clinicians to pull information from Mayo Clinic Laboratories' urine supersaturation test report. An updated format summarizes complex information to help guide the treatment of kidney stones.

(00:32)
 Could you tell us a little bit about yourself and your background?

 

(01:28)
 Could you give us a brief overview of urine supersaturation testing? How should it be used? How can it benefit providers and their patients?

 

(04:14)
 Can you tell us a little bit about the recent changes in our supersaturation tests and how they'll help providers better care for their patients?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest update on the U.S. Food and Drug Administration’s (FDA) proposed rule to oversee laboratory-developed tests (LDTs) and what that could mean for laboratories.

Specific topics of discussion include:

•  The FDA’s recent announcement on a proposed rule that would enable the agency to regulate LDTs, and what may happen next.
•  The impact that LDT regulation could have on clinical laboratories.
•  How to stay engaged and informed about regulatory issues.

Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment and family screening.

Show notes
Speaker 3: (00:31)
 Can you tell us a little about yourselves and your backgrounds?

 

Speaker 3: (01:33)
 Why is genetic counseling so important to our doctors and patients?

 

Speaker 3: (03:04)
 Can you give a brief overview of hereditary ataxia? 

 

Speaker 3: (04:24)
 Can you tell us more about Mayo Clinic's suite of molecular tests for various types of ataxia?

 

Speaker 3: (08:03)
 Are there any additional tests for hereditary ataxia at Mayo Clinic?

 

Speaker 3: (09:05)

When might a provider consider genetic testing for a patient?

 

Speaker 3: (10:05)
 Why is genetic testing important, and how are the results used?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about the evolution of remote diagnostics and how Mayo Clinic’s remote cardiovascular monitoring services empower physicians and patients. 

Specific topics of discussion include:

• How a comprehensive diagnostics ecosystem includes patient data beyond traditional laboratory specimens.
• An overview of Mayo Clinic’s Cardiovascular Services, a collaboration between Mayo Clinic Laboratories and Mayo Clinic’s Department of Cardiovascular Medicine, that enables physicians to remotely monitor patients’ heart functions from anywhere in real time.
• The role laboratorians can play in assessing and adopting new technologies that influence patient care.

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.

Speaker 2: (00:32)
 Could you provide a little bit about you and your background?

 

Speaker 2: (02:05)
 Can you please give a brief overview of this assay?

 

Speaker 2: (04:12)
 Which patients should have this testing and when should it be performed? 

 

Speaker 2: (07:17)
 Could you please go into detail about the changes we've made in this test?

 

Speaker 2: (11:46)
 How are the results used in patient care?

 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about the tick season peak that parts of the United States are experiencing, and how to diagnose and prevent Lyme disease.

Specific topics of discussion include:

• What parts of the United States have a heavy tick and Lyme disease presence.
• How Mayo Clinic identified the second known cause of Lyme disease, Borrelia mayonii.
• Typical and atypical presentations of Lyme disease, and testing options.
• How the laboratory plays a critical role in new test development and health care innovation.
• How to protect yourself and your pets from vector-borne diseases.

Research and discoveries in the biopharmaceutical industry drive health care innovation and lead to new therapies for patients. When laboratories collaborate with biopharma, diagnostic, and biotech companies, it creates an integrated diagnostic ecosystem that can improve global health.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about the role of the biopharma industry and how Mayo Clinic BioPharma Diagnostics is fostering a diagnostic ecosystem.

Specific topics of discussion include:

·       The importance of the biopharma industry working across the spectrum of diagnostics.

·       An overview of Mayo Clinic BioPharma Diagnostics.

·       New collaborations between Mayo Clinic, its diagnostic business lines, and industry partners. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Dong Chen, M.D., Ph.D., chair of the Division of Hematopathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic. They discuss rare and inherited platelet disorders and esoteric laboratory testing of hematologic disorders.

Specific topics of discussion include:

• How these rare disorders are diagnosed through laboratory tests.
• Why platelet transmission electron microscopy is considered the gold standard for diagnosing disorders like Hermansky Pudlak syndrome, Wiskott-Aldrich syndrome, Chediak Higashi syndrome, and Jacobson/Paris-Trousseau syndrome.
• The process involved with developing and validating the PTEM test (Mayo ID: PTEM) at Mayo Clinic.
• The importance of ongoing research and advocacy to enhance care for patients with rare platelet disorders.

Artificial intelligence (AI) can be an excellent tool for enhancing patient care and streamlining efficiencies in the lab. But because of its potential risks, AI must be thoughtfully and responsibly applied, both now and in the future. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to talk about how AI is impacting laboratories and pathology medicine.

Specific topics of discussion include:

• How AI and machine learning impacts laboratorians. 
• Examples of how Mayo Clinic is applying AI in its laboratory operations.
• Regulation and reimbursement questions surrounding digital pathology. 
• Potential impacts of new AI developments, such as ChatGPT.
• How pathologists can stay informed and engaged as AI progresses.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, talk about West Nile virus and why laboratories and the public need to be aware as mosquitoes reemerge.

Specific topics of discussion include:

• Why the mosquito is the deadliest animal in the world.
• Symptoms, testing options, and prevention strategies for West Nile virus infections.
• The importance of testing for West Nile virus.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss broader changes that are unfolding in the national and global diagnostic industry, and what to expect in the coming years.

Specific topics of discussion include:

• Reflecting on Dr. Morice’s recent participation in Executive War College and what’s on the minds of other diagnostic leaders.
• Thinking beyond the COVID-19 pandemic and about the future of diagnostics through a broader aperture.
• Understanding the international healthcare and laboratory medicine industries, and thoughts from Dr. Morice’s recent visit to Singapore.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, discuss endemic fungal infections that can be found in North America, specifically blastomycosis and histoplasmosis. 

Specific topics of discussion include:

• The basics of Blastomyces and Histoplasma fungi, which can cause serious lung infections.
• The recent blastomycosis outbreak at a Michigan paper mill.
• How these fungal infections are diagnosed in the laboratory.
• The cost-effectiveness of testing for the two pathogens with a single assay, and the importance of test stewardship.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, and special guest Susan Van Meter, president of the American Clinical Laboratory Association (ACLA). In celebration of Medical Laboratory Professionals Week, they discuss the critical role laboratories play in patient care and key legislative issues that impact the profession.

Specific topics of discussion include:

• Increasing understanding and visibility of the role of clinical laboratories.
• Reflecting on the common threads that bind all laboratory professionals together.
• Core lessons learned from the COVID-19 pandemic that can be applied to future virus outbreaks.
• Current federal legislation priorities for the laboratory industry.

Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.

(00:31)
 Can you provide our listeners with a little bit of background on your role at Mayo Clinic?

 

(01:56)
 Is Ma2 an example of identifying a need in patient care and then creating a test to fill that gap?

 

(02:30)
 Can you give us an overview of the disease state?

 

(04:29)
 What makes testing for these antibodies so complex?

 

(07:08)
 What specimen types are needed? Is there anything else our listeners should know about the assay itself?

 

(08:18)
 Ma2 will initially be a standalone test. But will these antibodies eventually be included in the movement disorder and encephalopathy tests?

 

(09:30)

Is it correct that roughly 80% of these patients have a cancer?

 

(10:41)

What types of patients should this testing be ordered for?

 

(13:39)

Is rapid onset part of the presentation?

 

(15:53)

Should any other testing be ordered in conjunction with Ma2?

 

(17:18)

How important is early, aggressive treatment for these patients?

 

(18:49)

What are you most excited about with this test launch?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Nancy Wengenack, Ph.D., director of the Mycology and Mycobacteriology Laboratories at Mayo Clinic, discuss the increased focus on fungi and why emerging fungal infections can be concerning for health care facilities.

Specific topics of discussion include:

• How fungi work inside and outside of the body.
• If it’s possible for fungal infections to turn animals, insects, and humans into zombies, as seen on the fictional show “The Last of Us.”
• Why emerging fungal pathogens like Candida auris are problematic.
• Laboratory diagnostics for fungal infections.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss how representation and advocacy make a difference in regulatory outcomes.

Specific topics of discussion include: 

• Why pathologists should be leading conversations about the future of health care.
• Advocating for issues facing the diagnostics industry, including reimbursement, workforce expansion, regulation, and oversight of laboratory developed tests.
• How laboratories can gain more visibility among policymakers and ensure their perspectives are considered.

Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test speeds therapeutic decision making for adults with acute myeloid leukemia, or AML. The standalone assay yields faster results than next generation sequencing.

(00:32)
 Would you provide a brief background of yourself?

 

(01:42)
 Could you give an overview of the IDHQ test?

 

(02:25)
 Is there anything more you'd like to touch on about the droplet digital PCR approach and high sensitivity?

 

(03:09)
 Why are IDH1 and IDH2 important in disease diagnosis, prognosis, or therapeutic management?

 

(05:00)
 Is there anything else you'd like to say about this particular assay?

 

(06:56)
 Would you describe the specific group of patients where testing is recommended?

In this test-specific episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Bjorn Oskarsson, M.D., a neurologist at Mayo Clinic’s Florida campus, discuss how the neurofilament light chain test available through Mayo Clinic Laboratories helps physicians diagnose neurological disease and assess neuronal damage.

Specific topics of discussion include:

• Benefits of the neurofilament light chain test that uses plasma rather than spinal fluid.
• How levels of neurofilament light chain – a nonspecific biomarker – play a role in clinical decision-making.
• How the test can be used to guide treatment options for neurological conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the latest news in pathogen activity and how these viruses serve as an important reminder of the role of the public-private lab partnership.

Their discussion includes:

• How the United States addresses emerging pathogens and the importance of a partnership between public health laboratories and private or clinical laboratories.
• Why access to testing is vital to prevent pathogen outbreaks and pandemics.
• The need for an effective legal framework around pandemic and hazard preparedness.
• Current diagnostic efforts around mpox, bird flu, and COVID-19, and opportunities to expand at-home testing.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss the increasing rates of tick-borne diseases and how to test for and prevent them. They also discuss what to watch from a federal legislative standpoint now that Congress is back in session.

Elitza Theel, Ph.D., explains how Mayo Clinic Laboratories' unique Histoplasma and Blastomyces test provides cost-effective evaluation for fungal infections that cause pulmonary illness. The assay reliably detects both Histoplasma and Blastomyces pathogens in a single test.

(00:32)
Will you please give us a brief introduction of yourself and your role at Mayo Clinic?

 

(01:34)
 Can you tell us which specific group of patients this test would be best suited for, how a provider would determine a patient might benefit from this test, and when during the care process it should be ordered?

 

(04:56)
 Can you explain how this new test is different, and why a provider might consider requesting it instead of the usual test?

 

(08:00)
 When should the different tests be used?

 

(09:34)
 Is this the only existing assay that can reliably detect antigen from both of these fungal pathogens?

Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the condition — or increase the risk of developing it.

(01:37)
 Can you give us a brief overview of the inherited Parkinson's disease gene panel, and when it would be used, Dr. Niu?

 

(02:31)
 Dr. Savica, can you give us a brief overview of the inherited Parkinson's disease gene panel, and when it would be used?

 

(03:34)
 What unique features set this test apart from the market, Dr. Niu?

 

(04:07)
 Dr. Savica, what features do you see that set this test apart in the market?

 

(05:19)

Who would benefit from this test, and when should it be performed?

 

(06:46)

Can you summarize the benefits of doing the inherited Parkinson's disease gene panel at Mayo, Dr. Niu?

 

(07:36)

Dr. Savica, can you summarize the benefits of doing the inherited Parkinson's disease gene panel at Mayo?

(00:31)
 Dr. Niu, could you provide us with a little bit of your background?

(01:03)
 Dr. Klein, could you provide us with a little bit of your background?

 

(01:40)
 Would you give us a brief overview of the new panel?

 

(02:49)
 Dr. Klein, could you give us a simple background of what you see going on in this space?

 

(03:33)
 Which patients should have this testing, and when should it be performed?

(04:49)
 Are there alternatives available, and how do they compare with this new MUPAN panel?

 

(05:51)
 How are the results used in patient care?

 

(07:24)

How does this new test affect patient care?

Many laboratorians are not patient-facing. So, while laboratories are critical to patient care, they may lack visibility when it comes to policymaking. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss their leadership roles in national advocacy organizations and the importance of laboratorian engagement in the federal regulatory process.

(00:31)
 Would each of you share a little bit about yourselves and your backgrounds?
 

(01:47)
 Could you provide us with an overview of what the WGSDX test is?

 

(02:26)
 How is that different from other genetic tests, like exome or microarray?

 

(03:56)
 Tell us more about who benefits from these tests.

 

(07:17)
 Is this test recommended by expert groups?

 

(09:10)
 How do providers go about ordering this test, and what sample types are accepted?

 

(11:12)
 What type of variants are detected by this test?

 

(13:04)
 How would you say our test matches up to other genome tests available on the market?

 

(14:04)
 What about medically actionable secondary findings?

 

(14:55)
 Are there any other unique features?

 

(16:07)
 Could you summarize the benefits of doing WGSDX at Mayo?

(00:31)
 Could you provide a little bit about yourself and your background?

 

(02:04)
 Could you provide an overview of the chromosomal microarray assay?

 

(05:49)
 Why should the chromosomal microarray assay be used over other available assays, such as FISH?

 

(08:56)
 Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification?

 

(12:03)
 What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel?

 

(17:20)
 How are the results used in patient care?

 

(19:41)

Is there anything else you feel it's important to highlight?

Norovirus is the No. 1 cause of foodborne illness in the United States. And while most people who contract norovirus recover on their own without the need for testing or treatment, others do not. 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, discuss what’s behind recent outbreaks of norovirus and how to keep yourself healthy and protected throughout the remainder of this year’s peak norovirus season. 

Matthew Schultz, Ph.D., and Amy White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

(00:31)
Would you share a little bit about yourself and your background?

 

(01:11)
 Could you provide us with an overview of this particular peripheral neuropathy? 

 

(03:09)
 Can you share the background as to how your team learned about this condition and how you considered testing for it?

 

(04:42)

Would you explain what you saw when you performed the urine test on the first patient?

 

(05:26)
 Were you able to test additional patients with this condition?

 

(06:09)

Could you expand on why this urine test is important?

 

(07:20)
 How does a health care provider order urine testing for SORD deficiency?

 

(07:59)
 How does this new SORD urine test complement the existing Mayo Clinic Laboratories test menu?

 

(08:55)

Could you summarize the benefits of ordering this SORD urine test at Mayo?

(00:31):

Before we get started, can you tell us a little bit about yourselves and your backgrounds?

(02:35):
Can you guys give us a brief overview of this assay and what will be changing to characterize marijuana use?

(04:28):
So which patients should have this testing and when would you say it should be performed, Dr. Langman?

(05:58):
Are there other test options available and if, and if so, how do these compare?

(07:03):
This is really the best way to accurately characterize marijuana use. Would you say that's true?

(07:11):
And then could you, Dr. Langman, explain how the results are used in patient care?

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories , joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Morice and Dr. Pritt discuss laboratory medicine from an international perspective: what advances are being made, how we educate future practitioners, and the need for global collaboration.

(00:32)
 Can you tell our audience a little bit about yourself and your role here at Mayo Clinic?

(01:29)
 Can you tell our listeners a little bit about the disease state when we talk about autoimmune or paraneoplastic movement disorders?

(02:37)
 Are we seeing an increased prevalence of autoimmune movement disorders?

(04:00)
 Can you give our listeners an overview of what's going to be launched here in January?

(06:56)
 What other antibodies are particularly important in this phenotype?

(10:01)
 How does the kelch-like protein 11 phenotype manifest in this disorder?

(10:49)
 Are there any antibodies in the autoimmune neurology space that would not need to be evaluated for in patients that present with some sort of movement disorder? 

(11:18)
 Which patients should have this testing and when should it be performed?

(12:55)
 When should Mayo Clinic Laboratories' stiff person evaluation and standalone glycine receptor tests be used, and in what order?

(14:40)
 Is the movement disorder evaluation the right first choice when the patient presentation is less typical and includes ataxia?

(16:42)
 Can physicians order the glycine receptor standalone test to fully evaluate the spectrum of antibodies?

(18:39)
 How does the evaluation impact patient care?

(20:12)
 Have these new antibodies been shown to be immunotherapy-responsive?

(20:27)
 Is there a key takeaway with the launch of these new antibodies in the movement disorder evaluation?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, sits down with Joaquin Garcia, M.D., chair of Mayo Clinic’s Division of Anatomic Pathology and digital pathology program to discuss how the advent of digital pathology is changing patient care at Mayo Clinic.

(00:31)
 Could you provide our listeners with a little bit about yourself and your background?

(01:48)
 Could you give an overview of the new neuro-oncology expanded gene panel by next generation sequencing?

 

(03:43)

Can you describe a little bit more about some examples of genes that were in the 2021 WHO classification that are now included in the NONCP panel?

 

(06:50)
 Does this panel have high clinical utility in both in adult and pediatric cases?

 

(08:05)
 Is picking up on copy numbers useful in both adult and pediatric cases?

 

(09:12)
 Could you discuss a little bit more about how these results would be used in patient care?

 

(10:27)
 Do you have anything else you would like to add about the enhanced neuro-oncology NGS panel?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., and William Morice II, M.D., Ph.D., provide an update on this year’s triple-demic of respiratory viruses, discuss the future of at-home testing, and preview future pandemic preparedness efforts.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Morice shares his biggest takeaways from this year’s J.P. Morgan Healthcare Conference in San Francisco, California, and gives an update on the COVID-19 public health emergency.

(00:32)
 Could you provide us with a little bit of your background?

(01:12)
 Could you give us an overview of this test and a summary of the assay?

(01:40)
 What kind of patients should expect to have this test ordered?

(04:11)
 Are other tests available that identify EDN activation in patients?

(05:11)
 How do you envision physicians using this test to treat patients?

(06:32)
 Can you expand on how the test is used in patient treatment?

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins Bobbi Pritt, M.D., on this week’s episode of the "Answers From the Lab" podcast. In this episode, they kick off the new year with a legislative update and discuss at-home testing options in the wake of the new subvariant of COVID-19.

Steven Ansell, M.D., Ph.D., chair of the Division of Hematology and senior deputy director, Midwest, Mayo Clinic Comprehensive Cancer Center, joins the "Answers From the Lab" podcast for a discussion with host Bobbi Pritt, M.D., about declining cancer death rates. In this episode, Dr. Ansell and Dr. Pritt discuss advancements in cancer treatments that are leading to declining death rates, the role diagnostics plays in cancer treatment, and what the future may hold for cancer diagnostics.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).

Their discussion includes:

• Symptoms of lupus and characteristics of the complex disease process.
• The role of laboratory testing in diagnosing and managing long-term treatment for patients with lupus.
• Dr. Thomas’ clinical experience using the Progentec aiSLE® DX Lupus Flare Risk Index and Lupus Disease Activity Index for his patients, and how these tests have enhanced collaborative treatment planning.
• Why these novel tests are a major step forward in expanding diagnostic tools and improving care for patients living with SLE.

Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, joins host Bobbi Pritt, M.D., on this week’s episode of the "Answers From the Lab" podcast. In this episode, they discuss the ongoing respiratory virus season, a new test for measles available at Mayo Clinic Laboratories, and some tips to stay healthy.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Drs. Pritt and Morice share their predictions for the new year and discuss why they believe 2023 will be a pivotal year for health care.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, joins “Answers From the Lab” for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Drs. Pritt and Morice discuss how offering specialty testing for conditions like Stiff-Person Syndrome and Alpha-Gal helps to advance innovation and give patients the answers they need.